Outcomes once deemed "almost too good to be true" disappeared with longer follow-up in an all-comer population of patients with diabetes undergoing revascularization.
A novel triple agonist targeting the GIP, GLP-1, and glucagon receptors produced unprecedented weight loss in patients with type 2 diabetes after 12 weeks on treatment in a safety study.
Study following people for over 30 years from the time of type 1 diabetes diagnosis finds increasing risk of complications with A1c levels above a certain threshold, increasing duration of disease.
The device was never approved in the US and its CE Mark was revoked in 2017 due to hepatic abscesses, but new data suggest the risk is lower than first reported.